Skip to search formSkip to main contentSkip to account menu

FCE 22250

Known as: FCE-22250, Rifamycin, 3-(methyl(1-piperidinylmethylene)hydrazino)- 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Rifamycins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1998
Review
1998
[Chemotherapeutic agents under study].
The development of new drugs with strong antituberculous activity and fewer side effects which are not cross-resistant to… 
1991
1991
[Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats].
After rats being given ig FCE 22250 5, 10 and 25 mg.kg-1, the plasma peak times (Tmax) were 12-14 h, the max plasma… 
1985
1985
Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250.
FCE 22250 (3-(N-piperidinomethylazino)methylrifamycin SV) is a member of the new class of 3-azinomethylrifamycins characterized… 
1985
1985
Physico-chemical properties of FCE 22250, 3-(piperidinomethylazinomethyl)rifamycin SV, a new long-acting rifamycin.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)